Uveal melanoma is the most common primary intraocular malignant tumor in adults and half of the primary tumors will develop fatal metastatic disease to the liver and the lung. Crizotinib, an inhibitor of c-Met, anaplastic lymphoma kinase (ALK) and ROS1, inhibited the phosphorylation of the c-Met receptor but not of ALK or ROS1 in uveal melanoma cells and tumor tissue.
INTRODUCTION
Uveal melanoma is the most common primary intraocular malignant tumor in adults. Tumor epicenters are usually found in the choroid but may also arise from the iris and ciliary body.
About 45% of uveal melanoma cases were recorded in adults over 60 years old and 53% were in adults aged between 21 and 60 years old (1) . The 5-year survival rate of uveal melanoma patients from 1973-2008 is 81.6% (2) . However, the prognosis is worse for patients that develop metastatic uveal melanoma with an overall 1-and 2-year survival rates of 13% and 8%, respectively (3, 4) . About half of patients with uveal melanoma will develop metastasis, which primarily occurs in the liver (5, 6) . In fact, nearly all uveal melanoma patients that die due to metastatic disease have liver metastasis (7) . Uveal melanomas are characterized by mutations in the G-protein genes, GNAQ and GNA11. Although the loss of chromosome 3 (5, 8) and mutations in the BAP1 gene are additionally implicated in uveal melanoma metastasis (9, 10) , there has been a considerable interest on the possible role of c-Met which is highly expressed in metastatic uveal melanoma tumors (5, 11) .
The receptor tyrosine kinase, c-Met, is a 140-kDa transmembrane protein consisting of a disulfide-linked heterodimer with an extracellular Į-subunit and a transmembrane ȕ-subunit.
When c-Met is bound to its ligand, hepatocyte growth factor (HGF), the autophosphorylation of tyrosine residues are initiated at Tyr1230/1234/1235 in the catalytic domain propagating a signaling cascade through a number of adaptor and effector proteins. This signaling results in the activation of the Ras-ERK, STAT and PI3K-AKT pathways which are implicated in oncogenic cell proliferation, survival and motility (12) (13) (14) . However, a study has shown that the activation of the previously mentioned pathways through c-Met signaling may not be enough to induce mitogenesis in the cells (15) . Other receptor tyrosine kinases, namely epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and insulin-like growth factor 1 receptor (IGF1R) may work in conjunction with or propagate the activation of cMet to initiate mitogenic pathways (6, 16, 17) . Previous studies have shown that HGF influences migratory ability in vitro (18) and its self-expression may contribute to metastasis in vivo.
Activated c-Met, a result of indirect gene activation rather than mutation, has also been found in uveal melanoma cell lines (19) . Furthermore, previous studies have implicated the increased expression of c-Met in primary uveal melanoma tumors with the higher risk of liver metastasis (6, 11) .
Crizotinib is a small molecule inhibitor that is selective for c-Met as well as anaplastic lymphoma kinase (ALK) and (ROS1). It has been shown to inhibit cell proliferation, migration and invasion of several tumor cell lines in vitro and it has also displayed significant antitumor activity in xenograft mouse models (20) (21) (22) . It is approved for the treatment of ALK-expressing advanced and metastatic non-small cell lung cancer. Since the survival rate of uveal melanoma patients decreases as metastatic disease progresses and that previous studies suggest the significant role of c-Met in uveal melanoma metastasis, there may also be a potential for using crizotinib to prevent the development of metastatic uveal melanoma. This study, therefore, investigates the effects of crizotinib in uveal melanoma cell lines and in a metastatic uveal melanoma model. 92.1 and Omm1.3 had GNAQ mutation while Omm1 had GNA11 mutation. A karyotype test was also performed for each cell line in 2012. Cells were cultured in RPMI medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin and maintained at 37°C in 5% CO 2 . Crizotinib, graciously supplied by Pfizer (La Jolla, CA), was dissolved in dimethyl sulfoxide (DMSO) for in vitro experiments and formulated in water for animal studies.
MATERIALS AND METHODS

Cell culture and reagents
C918 and
ELISA
For each uveal melanoma cell line, 2 million cells were used to seed 60 mm plates in 3 mL volume of serum-free RPMI media in duplicates. Cells were allowed to grow for 24 hours and the media were collected and centrifuged. The supernatants were used in the R&D Systems Quantikine® ELISA Human HGF Immunoassay according to the manufacturer's instructions.
Serum-free media from unseeded plates were used to subtract the background. The presence of HGF in the media is expressed as pg/mL concentrations and the minimum detectable dose of the assay is less than 40 pg/mL.
Immunoblotting
Cells and tissues were lysed with radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor cocktail tablets (Roche Diagnostics) and 1 mmol/L Na 3 VO4. Equal amounts of protein were loaded on 4% to 12% PAGE gels (Invitrogen, Carlsbad, CA).
Polyvinylidene difluoride (PVDF) membranes were blocked with 5% nonfat dried milk and 
Construct and preparation of recombinant lentivirus
An FUGW-based lentiviral vector encoding EGFP/luciferase fusion gene (FUGLW) under the ubiquitin promoter was used to infect the uveal melanoma tumor cells. The viral supernatant was prepared by cotransfecting 293T cells with the FUGLW, pCMV-d8.91and pMD2.G vectors.
Viral transduction was performed as previously described by Dogan et al (28) .
Metastatic model
Omm1. . All efforts were made to minimize suffering.
Bioluminescence imaging in vivo
The imaging procedure was performed under 2.5% isoflurane anesthesia. The animals were 
Histopathology
For immunohistochemical analysis, representative sections of tumors were de-paraffinized, rehydrated in graded alcohols, and subjected to antigen retrieval by microwave oven treatment using standard procedures. H&E staining was carried out using Gill's hematoxylin (Poly Scientific R&D Corp., Bay Shore, NY, USA) for 10 min as per the manufacturer's protocol, followed by counterstaining with eosin (Poly Scientific R&D Corp., Bay Shore, NY) for 4 min.
The immunohistochemistry was performed at the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center using MIRAX Slide Scanning System (PerkinElmer, Waltham, MA).
Statistical analysis
All in vitro experiments were carried out at least 2-3 times. For in vitro and in vivo studies, P values were calculated using Student's t-Test. We selected P values 0.05 as being statistically significant. Standard error was calculated as the standard deviation divided by the square root of the number of samples.
RESULTS c-Met expression and HGF secretion in uveal melanoma cells
We evaluated the expression of the c-Met receptor and its basal phosphorylation status in uveal melanoma cells grown in serum-free media for 24 hours (Fig. 1A) . Fig. 2A and Fig. 2B ). In cell viability assays, cell growth was not affected by c-Met knockdown (Fig. 2C) . On the other hand, c-Met siRNA significantly inhibited cell migration (p < 0.05) ( Fig. 2D and Supplementary Fig. 1 ) and this effect was independent of Gprotein status. In view of the fact that crizotinib is also an inhibitor of ALK and ROS1 kinases, we employed the siRNA knockdown strategy in suppressing ALK and ROS1 (Fig. 2B ) to investigate whether these kinases have any effect in uveal melanoma migration. ALK and ROS1
knockdown did not significantly inhibit the migration of uveal melanoma cells (Fig. 2D and Supplementary Fig. 1 ). There was a slight decrease in migration of Omm1 cells transfected with ALK and ROS1 siRNA, but it was not statistically significant (p > 0.05). Collectively, these results indicate that cell migration of uveal melanoma cells is dependent on activated c-Met but not ALK or ROS1 and selectively suppressing c-Met decreases cell migration.
Crizotinib inhibits migration of uveal melanoma cell lines
We next elected to determine whether crizotinib would have a similar effect on cell migration.
For these studies, we wanted to select the minimal concentration necessary to selectively inhibit p-Met but would have no effect on cell growth. The effects of crizotinib on the cell growth of uveal melanoma cell lines, wild-type (WT) or mutant for GNAQ and GNA11, were evaluated using a range of concentrations from 10 nmol/L to 3000 nmol/L (Fig. 3A) . After 72 hours of treatment, all uveal melanoma cell lines showed a dose-dependent decrease in cell viability in response to crizotinib treatment. However, this effect only occurred at doses 1,000 nmol/L.
We found that c-Met phosphorylation was inhibited by crizotinib starting at 25 nmol/L, while neither ALK nor ROS1 was inhibited at any of the concentrations tested with 24 hours of drug exposure (Fig 3B) . In view of this, we elected to test crizotinib at 25 nmol/L in a 24-hour migration assay. As shown in figure 3C , when uveal melanoma cells were treated with 25 nmol/L of crizotinib, a mutation-dependent effect was observed such that only the migration of G-protein mutant cells lines and not G-protein wild type cell lines (C918 and Mel290) was decreased. However, when treated with 250 nmol/L crizotinib for 24 hours (conditions under which cell proliferation was still not affected), the migration of all cell lines was inhibited irrespective of mutational status ( Supplementary Fig. 2 ), suggesting that G-protein mutant cells with higher basal activity of c-Met ( Figures 1A and 3B ) are sensitive to lower concentrations of the drug.
Crizotinib has marginal effects on tumor growth inhibition in uveal melanoma xenografts
To (Fig. 4C) . Although, the administration of this drug dose resulted in a complete inhibition of phosphorylation of c-Met, there was no inhibition in phosphorylation of the other target kinases, p-ALK and p-ROS1. Importantly, the common downstream signaling components also appeared to be generally unaffected as determined by unchanged levels of p-AKT, p-ERK and p-STAT3. There was a slight decrease in p-ERK1/2 in the Omm1.3 cells, though this could be due to a decrease in total ERK1/2 protein expression.
The detection of human HGF expression in the tumor xenografts supports the hypothesis that HGF may activate c-Met through an autocrine activating loop in these cells. Apoptosis signaling at least via PARP cleavage was not observed in this study. There was no significant weight loss with this dose of crizotinib in either animal study ( Supplementary Fig. 3A and 3B) and also attempts to increase the drug dose to 75 and 100 mg/kg respectively also showed no appreciable reduction in tumor volume though this was associated with some modest weight loss (Supplementary Fig. 4A and 4B ).
Crizotinib prevents macrometastasis of uveal melanoma cells from developing in vivo
As there was only a minimal inhibition of tumor growth in vivo and that crizotinib inhibits (Fig. 5C ). There was bioluminescence signal in the lungs of untreated animals, yet again there were no detectable bioluminescence signal in the lungs of treated animals. It is important to note that the uveal melanoma tumor growth in the eye of the mice was not inhibited by crizotinib. An H&E staining of liver sections from both cohorts verified the presence of metastatic tumor in the liver of untreated mice but not in the liver of crizotinibtreated mice (Fig. 5D) . Two weeks after the end of drug treatment (i.e., on week 11), bioluminescence imaging showed continued tumor growth in the eye (the primary site), and in multiple distant sites, when compared to the mice treated with crizotinib ( Supplementary Fig.   5A ). In crizotinib-treated mice, metastases largely remained inhibited. Necropsy of the vehicle treated mice revealed bioluminescence in the liver, lung, kidney and spleen ( Supplementary Fig.   5B ). In addition, at week 11 the mice that previously responded to crizotinib now revealed small metastases in the liver.
DISCUSSION
The development of macroscopically detectable metastasis occurs in 50% of patients with uveal melanoma within 15 years of initial diagnosis, even after treatment and removal of the primary tumor (29) . In our study, crizotinib inhibited c-Met phosphorylation and prevented uveal melanoma from forming macroscopic metastatic disease in a mouse model. We also observed a lack of anti-proliferative effects by crizotinib at doses that selectively inhibit only c-Met. Other studies have shown hepatic, bone and visceral micrometastasis develop in a uveal melanoma xenograft model (34) , as well as bone and visceral macrometastasis in an intracardiac metastatic mouse model (35) . Another study has also demonstrated inhibition of micrometastasis using a VEGFR inhibitor after enucleation of the mouse eyes (36) . In our study, we show that liver and lung metastases develop six to seven weeks after retro-orbital injection of EGFP-luciferase-infected uveal melanoma cells. We then demonstrated that crizotinib, at concentrations that inhibit p-Met in vivo, inhibited metastases from forming in the liver and lungs of the treated mice as compared to the control mice. We also observed that two weeks after stopping treatment with crizotinib, the mice previously treated with the drug showed traces of metastasis in the liver, but this was still significantly less than the control mice. The subsequent progression of metastasis after termination of treatment further illustrates the dependence of metastatic disease on c-Met signaling. It also illustrates that crizotinib is unable to kill the microscopic metastases that develop rapidly in both the liver and lungs after retroorbital injection, but rather it seems to either prevent the cells from migrating or spreading to dominant visceral sites, especially the liver. This inability to eradicate small volume disease ties in with the lack of single agent efficacy observed in our in vitro and in vivo studies. The detection of circulating malignant cells capable of developing hepatic micrometastasis has also been reported at the time of the initial diagnosis of patients with primary uveal melanoma (37) .
These cells may become dormant and later re-enter malignancy (38) . It is conceivable that crizotinib is able to control these cells as long as the drug is maintained and then this inhibitory effect is lost once the drug is withdrawn allowing metastatic lesions to develop.
Consistent with our in vitro and xenograft studies, we saw no inhibition of growth in the development of the eye lesions, even after the initiation of crizotinib therapy in the treated animals. Though this could be due to a lack of drug penetration into the orbit of the mouse, this is most likely consistent with our observation that inhibition of c-Met activity by crizotinib in uveal melanoma cells is in itself not sufficient to decrease tumor growth. Clinically, though, this is not a critical issue. Patients with primary uveal melanoma either have enucleation of the eye to remove the primary tumor or have plaque radiation to eradicate primary cancer cells at presentation. Despite this approach, 50% of patients eventually develop metastatic disease and reoccurrence in the eye is exceptionally low (5, 6) . The survival rate in uveal melanoma patients decreases dramatically with the onset of metastasis (3, 4) . Therefore, the critical issue remains how to prevent development of metastatic disease after the treatment of the primary tumor.
These results suggest that it will be important to introduce preventive therapy as early as possible after initial presentation of this disease and that this therapy may need to be continued for the life time of the patient. There is now the potential to develop crizotinib as the first adjuvant therapy to prevent macro-metastatic disease from developing in uveal melanoma patients. Furthermore, with the metastatic uveal melanoma model we developed, more drugs can be screened to identify effective inhibitors against c-Met-dependent metastasis. There was a decrease in migration of Omm1 cells transfected with ALK and ROS1 siRNA but it was not significant ( Ɣ p > 0.05). weeks (10 control mice, 12 treated mice). The mice were imaged for luciferase activity every week. A, bioluminescence imaging at 7 weeks after injection of cells compared progression of
